ST VINCENT HEALTHCARE
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $11.3M
- Transactions
- 1,450
- Companies
- 40
- Average per transaction
- $7,803
Who reported the payments
| Merck | $4,645,863 |
| Genentech, Inc. | $1,248,076 |
| Seagen Inc. | $855,145 |
| AbbVie | $552,302 |
| Eli Lilly | $404,023 |
| AstraZeneca | $369,873 |
| Exelixis Inc. | $355,466 |
| EMD Serono, Inc. | $352,880 |
| Beigene, Ltd. | $339,412 |
| Acerta Pharma LLC | $232,500 |
| Pfizer | $205,445 |
| AVEO Pharmaceuticals, Inc. | $203,046 |
| Ipsen Bioscience Inc. | $171,784 |
| E.r. Squibb & Sons, L.L.C. | $131,468 |
| Novartis | $121,562 |
| Mirati Therapeutics, Inc. | $121,313 |
| Gilead | $116,047 |
| Angiodynamics, Inc. | $111,417 |
| Ares Trading SA | $83,298 |
| Astrazeneca UK Limited | $74,059 |
| Bristol Myers Squibb | $63,300 |
| Sanofi US Services Inc. | $43,154 |
| Regeneron | $33,890 |
| Spectrum Pharmaceuticals Inc. | $33,499 |
| Medacta USA, Inc. | $32,926 |
| Daiichi Sankyo Inc. | $32,300 |
| Sumitomo Pharma America, Inc. | $31,700 |
| Beigene USA, Inc. | $30,559 |
| F. Hoffmann-la Roche AG | $30,508 |
| Bayer | $30,500 |
| Morphosys AG | $27,950 |
| United Therapeutics Corporation | $25,256 |
| Incyte Corporation | $18,041 |
| Beone Medicines Ltd. | $17,810 |
| Tolmar, Inc. | $15,570 |
| Astellas Pharma Global Development | $14,130 |
| Veloxis Pharmaceuticals, Inc. | $14,010 |
| Amgen | $13,565 |
| ADC Therapeutics America, Inc. | $13,397 |
| W. L. Gore & Associates, Inc. | $11,760 |